Effect of Extra Virgin Olive Oil Consumption on the Occurrence of Cardiovascular Events in Population Living With HIV

NCT07761819 | Not Yet Recruiting

• 1 other identifier: GESIDA 12725
• Study Type: interventional
• Target: 1,324
• Locations: 1 country
• Sites: 1

Brief Summary

Study Summary: OLEUM VIHTAEGeneral Information Sponsor: Fundación SEIMC - GESIDA Study Title: Effect of Extra Virgin Olive Oil (EVOO) consumption on the occurrence of cardiovascular events in people living with HIV. Protocol Code: GESIDA 12725 (Version 2.0, Jan 13, 2026) Study Design: National, multicenter, randomized, open-label clinical trial. Intervention Product: Extra Virgin Olive Oil (EVOO). Estimated Enrollment: 1,324 participants (662 per arm). Study Duration: Approximately 60 months (5 years) per participant. Objectives Primary Objective: To analyze the incidence of a composite index of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), including acute coronary syndrome, peripheral arterial disease, coronary/cerebral/peripheral revascularization, cerebrovascular disease, and cardiovascular or cerebrovascular death. Secondary Objectives: Incidence of individual cardiovascular events (Stroke, TIA, Heart Failure, Atrial Fibrillation). All-cause and cardiovascular mortality. Changes in metabolic and physical parameters (weight, blood pressure, glucose, lipid profile). Development of new comorbidities (HTA, DM2, Obesity) and initiation of related treatments. Exploratory sub-studies: Changes in gut microbiota, epigenetic aging markers, inflammation panels (96 cytokines), and urinary hydroxytyrosol levels. Study Population Key Inclusion Criteria: HIV-1 infected individuals (diagnosed ≥ 1 year). Age: 50 to 75 years. On Antiretroviral Therapy (ART) ≥ 1 year with suppressed viral load (\<50 copies/mL) for at least 6 months. Presence of at least one cardiovascular risk factor (HTA, DM2, high LDL, low HDL, smoking, or family history). Willingness to modify diet and no intolerance to EVOO. Key Exclusion Criteria: Pre-existing ischemic heart disease, cerebrovascular disease, or peripheral arterial disease. Calculated cardiovascular risk (RV10 ASCVD) \< 5%. Life expectancy \< 1 year or inability to complete the study. Severe comorbidities: Stage C Cirrhosis, end-stage renal failure, dementia, or active malignancy. Current high EVOO intake (≥30 mL/daily). Treatment Plan Participants will be randomized (1:1 ratio) into two groups: EVOO Group: Daily intake of 50 mL of Extra Virgin Olive Oil. Control Group: Continuation of their usual diet (verified as not rich in EVOO). Statistical Analysis \& Monitoring Primary Endpoint: Proportion of patients meeting the composite cardiovascular morbidity/mortality index at 5 years. Methodology: Analysis by protocol and intention-to-treat (ITT) using SPSS v28. Generalized linear models for repeated measures, adjusted for covariates. Interim Analysis: Planned for Year 2 and Year 4. Ethics Board (Board Affiliation): CEIm Hospital Costa del Sol, Marbella, Spain.

Conditions

HIV - Human Immunodeficiency Virus

Keywords

cardiovascular; extra virgin olive oil; HIV; elderly population; Gut microbiota; Epigenetic age; Hydroxytyrosol; Inflamm-aging; Inflammatory biomarkers

Outcome Measures

Primary Outcomes (1)

• Proportion of participants with a major cardiovascular event or cardiovascular/cerebrovascular death

  Proportion of participants who experience a composite cardiovascular outcome consisting of acute coronary syndrome, peripheral arterial disease, arterial revascularization (coronary, cerebral, or peripheral), cerebrovascular disease, or cardiovascular or cerebrovascular death.

  From randomization until the first occurrence of a component of the composite outcome or the end of study follow-up, assessed up to 5 years.

Secondary Outcomes (1)

• Proportion of participants who die from any cause

  From randomization until death or the end of study follow-up, assessed up to 5 years.

Study Arms (2)

Extra Virgin Olive Oil Arm

EXPERIMENTAL

The patients enrolled in this arm must ingest 50 mL of extra virgin olive oil daily

Dietary Supplement: The patients must ingest 50 mL of extra virgin olive oil daily

No Extra Virgin Olive Oil Arm

NO INTERVENTION

No Intervention

Interventions

The patients must ingest 50 mL of extra virgin olive oil daily DIETARY_SUPPLEMENT

Cardiovascular risk analysis in HIV elder patients ingesting 50 mL of extra virgin olive oil daily

Extra Virgin Olive Oil Arm

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• HIV-1 infection with at least one year since diagnosis
• Ability to sign the informed consent form
• Age between 50 and 75 years (including those who have already turned 50 and those under 76) at the time of signing the informed consent form
• ART for at least one year, with a viral load \<50 copies/mL for at least the last year, or elite controller (Western Blot serology + with viral loads \<50 copies/mL in the absence of ART)
• HIV-1 viral load ≤50 copies/mL for at least 6 months prior to signing the consent form. If the viral load is \>50 copies/mL at the baseline visit, the participant will not be excluded and the investigator will act in accordance with standard clinical practice.
• If in the previous 6 months the participant has had an isolated viral load of \<200 copies/mL with another subsequent viral load \<50 copies/mL, entry into the trial will be accepted provided that in the 12 months prior to entry into the trial there was only one isolated detectable determination.
• No reported intolerance to EVOO
• Willingness to change diet
• Presence of at least one of the following risk factors: hypertension, DM2, high LDL cholesterol, low HDL, high lipoprotein (a), tobacco use, first-degree family history of early cardiovascular disease (\<55 years in men or \<65 years in women)

You may not qualify if:

• Presence of ischemic heart disease, cerebrovascular disease, or peripheral arterial disease in any form.
• Cardiovascular risk calculated by ASCVD VR10 less than 5%.
• Life expectancy of less than one year in the investigator's opinion.
• Inability to complete the study in the investigator's opinion.
• Presence of Child stage C cirrhosis, end-stage renal failure (eGFR by CKD-EPI \<10 mL/min or dialysis in any form), dementia.
• Current diagnosis of wasting syndrome or BMI\>40
• Inability to follow a Mediterranean diet
• Institutionalized or dependent patients
• Presence of diseases or conditions that, in the investigator's opinion, may hinder absorption.
• Reported intake of at least 30 mL of EVOO per day (equivalent to two tablespoons of oil)

Sponsors & Collaborators

• Fundacion SEIMC-GESIDA: lead

Study Sites (1)

Hospital Universitario Costa del Sol

Marbella, Málaga, 29603, Spain

Location

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Condition Hierarchy (Ancestors)

HIV Infections; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases

Central Study Contacts

Julián Olalla

CONTACT

034951293854; julio.olalla@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 30, 2026
• First Posted: August 12, 2026
• Study Start (Estimated): October 31, 2026
• Primary Completion (Estimated): June 15, 2031
• Study Completion (Estimated): December 15, 2031
• Last Updated: August 12, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

ES (1)